Dana dhuwit perusahaan: Halozyme (HALO)

Simbol resmi perusahaan Halozyme Corp (HALO)

ENHANZE patents and stringent FDA oversight create an insurmountable barrier for competitors. Stable royalties render the business insensitive to market volatility. The cash trajectory clearly demonstrates liquidity, where the value of 1.07 captures the metric level. Halozyme Therapeutics (HALO) growth relies on the success of clinical trials and the rollout of innovations, ensuring independence from economic cycles.

HALO - Cadangan dhuwit perusahaan Halozyme Corp ing rentang 04.07.2022 - 21.11.2026

Rincian metrik komprehensif lan analitis Halozyme (HALO)

Pambiji fundamental:Halozyme Therapeutics, Inc.
Sampel barang halozyme.com

Halozyme Therapeutics (HALO) utilizes a high-margin licensing model for its ENHANZE technology, minimizing capital expenditures. This indicator captures the absolute volume of liquid assets, allowing for the tracking of real capital accumulation trends. By analyzing operating cash flow, an investor assesses the business's ability to accumulate resources without commercialization risk. The steady growth of this metric confirms the exceptional resilience of the asset-light structure and the predictability of cash flows.

Pesaing Halozyme Therapeutics (HALO)

Volume dana dhuwit perusahaan ONC|Volume dana dhuwit perusahaan Revolution Medicines, Inc. (RVMD)|Volume dana dhuwit perusahaan AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cadangan dhuwit perusahaan|URGN - Dana dhuwit perusahaan|Bicara Bio - Gunggung dana dhuwit perusahaan|PSNL: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan ERAS|Dhuwit awis perusahaan DCTH|Cadangan dhuwit perusahaan Y-mAbs Therapeutics Inc YMAB|Volume dana dhuwit perusahaan AURA|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan